Articles from Lumos Pharma, Inc.

AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right (“CVR”) for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events relating to the level of annual global net revenue of LUM-201 up to the year 2037, different transactions involving Lumos Pharma or its assets that occur within 18 months of closing or certain sales, license or similar revenue-generating agreements entered into within 18 months of closing and that are related to Lumos Pharma’s legacy products other than LUM-201. There can be no assurance any payments will be made with respect to the CVRs. The purchase price of $4.25 per share represents a total equity value of approximately $38 million, a premium of 7.6% to Lumos Pharma’s closing share price of $3.95 on October 22, 2024, and a premium of 10.5% to Lumos Pharma’s 30-trading-day volume weighted average price as of October 22, 2024.

AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK.

AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQLUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK.

Lumos Pharma and the FDA Align on Final Design for Global, Double-blinded, Placebo-Controlled Phase 3 Trial Evaluating Oral LUM-201 in PGHD

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand.

AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile.

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9th – 11th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9th and 10th.

Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency

AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, MA, June 1-4, 2024. The posters were presented in parallel sessions on Monday June 3, 2024.

AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1-4, 2024.

Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.

AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company received a Notice of Allowance from the US Patent and Trade Office (USPTO) for claims in its patent application number PCT/US22/050700 titled “Compactable Oral Formulations of Ibutamoren.” This patent contains claims directed to certain improved formulations of LUM-201 the Company intends to utilize in its Phase 3 trial and ultimately commercialize. This grant of this novel formulation patent extends intellectual property protection through November 2042 for these improved versions of LUM-201 drug product.

End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Lumos Pharma’s management will present and host virtual one-on-one meetings with the investment community on Wednesday, February 14 during the event.

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (CMO), effective January 1, 2024. In this role, Dr. Pitukcheewanont will provide his leadership in Lumos Pharma's efforts to hone its clinical and regulatory strategy, and he will continue to oversee medical affairs as the Company prepares to initiate its pivotal Phase 3 trial evaluating the efficacy of oral LUM-201 in treating moderate pediatric growth hormone deficiency (PGHD).

Webinar to be Held December 6, 2023 at 1:30pm EST

AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference being held November 28th – 30th in New York City. Lumos Pharma management will present and host one-on-one meetings at the conference.

-- Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 –

Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an analysis of interim data from its OraGrowtH212 Trial was given as an oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology (ESPE), held in The Hague, Netherlands, September 21-23, 2023.

AUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an abstract reviewing interim data from its OraGrowtH212 Trial has been accepted for oral presentation at the 2023 annual meeting of the European Society for Paediatric Endocrinology, to be held in The Hague, Netherlands, September 21-23, 2023.

AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th – 13th and the Cantor Global Healthcare Conference 2023 being held September 26th – 28th in New York City. Lumos Pharma management will present and host one-on-one meetings at both conferences.

Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time

AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, today announced financial results for the second quarter ended June 30, 2023.

AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its second quarter 2023 financial results after market close on Wednesday, August 9, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company’s President & Chief Scientific Officer, John McKew, PhD, will participate in the Oppenheimer 2023 Life Sciences Summit to be held July 18th – 20th in Montauk, NY, during which discussions with investors will take place.

AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) Dr. David B. Karpf is departing the company to pursue other opportunities, effective June 29th. Dr. Pisit “Duke” Pitukcheewanont, Lumos Pharma’s Senior Vice President, Global Clinical Development and Medical Affairs, along with other members of our clinical team, will oversee all clinical activities and related functions until a CMO search is complete.

Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response

AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 2023 BIO International Convention held June 5-8, 2023 in Boston and the Jefferies Healthcare Conference held June 7-9, 2023 in New York City. Lumos Pharma management will present and host one-on-one meetings at both conferences.

KOL Webinar to be held June 21, 2023 at 11:00 AM Eastern Time

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that management will participate in panel discussions at the World Orphan Drug Congress USA 2023, held in Washington, D.C., May 23-25, 2023. John McKew, PhD, the Company’s President and Chief Scientific Officer, and Aaron Schuchart, its Chief Business Officer, will be participating in panel discussions as follows:

Oral and Poster Presentations on OraGrowtH Trials at PES 2023 Further Support Potential for LUM-201 as First Oral Treatment for Moderate Idiopathic PGHD

-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials ---- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 ---- Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 –-- Conference Call Scheduled for Today at 4:30pm ET --

Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in Oppenheimer’s 33rd Annual Healthcare Conference held virtually March 13-15, 2023. Lumos Pharma will present and host virtual one-on-one meetings with the investment community on Tuesday, March 14th, during the event.

Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis

-- Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials --

Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled

AUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2022 financial results after market close on Wednesday, March 1, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12th Annual LifeSci Partners Corporate Access Event held in San Francisco January 9-11, 2023. Lumos Pharma will host in-person one-on-one meetings with the investment and biopharmaceutical community on Tuesday and Wednesday, January 10th and 11th, during the event.

AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Company’s interim data from two Phase 2 trials evaluating oral LUM-201 in moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD). Andrew Dauber, MD, MMSc, Chief of Endocrinology, Children’s National Hospital, and Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile, discussed recently released (on November 14, 2022) and new interim data (presented on December 6, 2022) from two ongoing OraGrowtH trials.

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). The KOL webinar will take place on December 6th at 2:00 PM EST.

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st.

-- Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six months for the LUM-201 Dose of 1.6 mg/kg/day in the OraGrowtH210 Trial which Supports Advanced Planning for Pivotal Phase 3 Trial --

- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) -

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQLUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks.